Yusuke Nakamura to Drug Therapy, Combination
This is a "connection" page, showing publications Yusuke Nakamura has written about Drug Therapy, Combination.
Connection Strength
0.205
-
The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation. PLoS One. 2018; 13(8):e0202272.
Score: 0.035
-
Genetic variants associated with angiotensin-converting enzyme inhibitor-associated angioedema. Pharmacogenet Genomics. 2013 Sep; 23(9):470-8.
Score: 0.025
-
Toward the establishment of a prediction system for the personalized treatment of chronic hepatitis C. J Infect Dis. 2012 Jan 15; 205(2):204-10.
Score: 0.022
-
Inverse association of IL28B genotype and liver mRNA expression of genes promoting or suppressing antiviral state. J Med Virol. 2011 Sep; 83(9):1597-607.
Score: 0.021
-
Prediction of response to peginterferon-alfa-2b plus ribavirin therapy in Japanese patients infected with hepatitis C virus genotype 1b. J Med Virol. 2011 Jun; 83(6):981-8.
Score: 0.021
-
Common genetic polymorphism of ITPA gene affects ribavirin-induced anemia and effect of peg-interferon plus ribavirin therapy. J Med Virol. 2011 Jun; 83(6):1048-57.
Score: 0.021
-
IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy. J Hepatol. 2011 Jun; 54(6):1094-101.
Score: 0.020
-
Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir. Hepatology. 2011 Feb; 53(2):415-21.
Score: 0.020
-
HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy. Gut. 2011 Feb; 60(2):261-7.
Score: 0.020